Background-Activation of leukocytes with release of myeloperoxidase (MPO) has been linked to acute coronary disease. To date, studies investigating the diagnostic and prognostic performance of circulating MPO in patients with chest pain (CP) are mainly retrospective, of low size, and lack a cut-off value for MPO. Herein, we prospectively assess the diagnostic and prognostic properties of MPO compared with sensitive troponin I (sTNI) in patients admitted to the emergency room with CP. Methods and Results-One thousand, eight hundred and eighteen consecutive patients (mean age, 61.4±13.5 years; 33.6% female) admitted for CP underwent determination of MPO, sTnI, and B-natriuretic peptide plasma levels at admission and 3 hours and 6 hours thereafter. A cut-off for MPO was defined in 5000 population-based subjects. Baseline MPO levels were elevated in patients with acute myocardial infarction compared with patients with noncoronary CP. For all time-points accuracy of MPO was inferior to sTNI for predicting AMI. The sensitivity of MPO to diagnose AMI at presentation was 73.5% compared with 90.7% for sTNI, and the specificity of MPO was 45.5% as opposed to 90.2%. B-natriuretic peptide levels also failed to demonstrate independent diagnostic information. Both MPO and B-natriuretic peptide were predictive for increased risk of adverse events at 30 days and 6 months, whereas their predictive value was weakened after covariate adjustment. Conclusions-The data demonstrate that MPO and B-natriuretic peptide fail to provide incremental information for patients with acute onset CP when added to sensitive troponin. However, there is a potential value for both biomarkers as prognostic markers. (Circ Cardiovasc Genet. 2012;5:561-568.)
A ccumulating evidence suggests that activation of leukocytes, and in particular polymorphonuclear neutrophils with concomitant release of the heme-enzyme myeloperoxidase (MPO), is closely linked to coronary plaque injury, and thus an early event in acute coronary disease. [1] [2] [3] [4] These observations are accompanied by a host of preclinical studies demonstrating a pathophysiological role for MPO throughout all stages of atherosclerotic lesion formation. In fact, MPO demonstrated to promote endothelial dysfunction by oxidizing endothelial nitric oxide 5, 6 and oxidatively converting low-density and high-density lipoproteins to proatherogenic derivatives. 7, 8 Also, MPO has been shown to activate matrix metalloproteinases, enzymes involved in plaque rupture, and myocardial fibrosis. 9 Moreover, MPO adversely affected myocardial remodeling, thereby adding to its potential mechanistic involvement in heart failure. 10 
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Consequently, numerous recent studies have sought to evaluate the use of MPO plasma levels as a biomarker in patients with suspected or manifest acute coronary syndrome (ACS). The fact that MPO release from leukocytes is connected to plaque rupture rather than solely myocardial injury stimulated investigations assessing the clinical value of MPO plasma levels as early markers of ACS. Indeed, recent studies indicated that the increase of MPO plasma levels precedes myocardial tissue injury 4 and suggested a potential for MPO as a diagnostic marker with high negative predictive value (NPV) complementing troponins by facilitating to rule out ACS in patients presenting early after chest pain (CP) onset. 11 However, other studies failed to show a diagnostic utility of MPO plasma levels in ACS patients. 12, 13 Part of these discrepancies may reflect the overall limited number of patients enrolled, the retrospective nature of most of the studies, and differences in patient population and study design, respectively. More importantly, however, all studies so far used an arbitrary cut-off value for MPO rather than defining a cut-off based on population-based subjects. In addition, the advent of sensitive troponins, which have been shown to be superior for the diagnosis of myocardial infarction compared with the previous assays, 14, 15 calls for an in-depth evaluation of MPO plasma levels as compared with state-of-the-art determination of troponins.
Methods

Study Population
The study population consisted of 1818 consecutive patients presenting with acute CP to 3 German study centers (Johannes Gutenberg University Medical Center Mainz, Federal Armed Forces Hospital Koblenz, and University Heart Center Hamburg), enrolled from January 2007 to December 2008. A detailed description of the study population is provided elsewhere.
14 Determination of MPO plasma levels was one of multiple markers the study was designed for, and thus a prespecified parameter to be tested. The study was approved by the local ethics committees in Hamburg and Rheinland-Pfalz and all patients gave written informed consent before enrolment. Blood samples for determination of biomarker levels were obtained at 0 hours, 3 hours, and 6 hours after admission of the patients. MPO was measured from Ethylenediaminetetraacetic acid (EDTA) plasma for the current study and for the Gutenberg Health Study, a population-based study, which was used to derive a cut-off value for MPO. For both studies, sample collection was performed according to a strict study protocol which allowed a time interval of 90 minutes between blood withdrawal and sample storage at −80°C. 16 All patients were followed up 6 months after initial hospitalization. Information about cause of death or clinical events was obtained from hospital or general practitioner charts. Additionally, the local civil registry office provided information about death. Outcome measure was the composite of cardiovascular death and nonfatal myocardial infarction. Nonfatal myocardial infarction, the potential myocardial infarction leading to initial hospitalization, was excluded as an end point. The end point of death from cardiovascular causes included fatal myocardial infarction, sudden cardiac death, death caused by congestive heart failure, and death attributable to other cardiac or causes.
Adjudication of Final Diagnosis
The final discharge diagnosis was determined as previously described. 14 In brief, the diagnosis was adjudicated by a committee of 2 independent cardiologists who were unaware of MPO plasma levels and levels of sensitive troponin I. Primary diagnosis of acute myocardial infarction (AMI) was based on current guidelines, provided evidence of myocardial necrosis was indicated by conventional troponin assays. Consistency of myocardial necrosis with myocardial ischemia was evidenced by typical symptoms, electrocardiographic changes of new ischemia (new ST-segment or T-wave changes or new left bundle-branch block), new loss of viable myocardium using imaging techniques or detection of a culprit lesion by coronary angiography. The diagnosis of unstable angina was made in the case of negative serial conventional troponin tests and nondiagnostic electrocardiograms, but evidence of ischemia as indicated by the need for intervention during coronary angiography or positive stress test with subsequent diagnosis of coronary artery disease by coronary angiography.
Measurement of MPO and Sensitive Troponin I
Myeloperoxidase levels were determined by a commercially available ELISA (CardioMPO assay, Cleveland HeartLab) from EDTA plasma. To determine cut-off values for MPO, the enzyme was also measured in 5000 population-based subjects from the Gutenberg Health Study; a value of 517.2 pmol/L was determined as cut-off value for MPO, which was the 95th percentile of MPO plasma levels determined. B-natriuretic peptide (BNP) levels were determined by immunoassay (Abbott Diagnostics).
As indicated previously, the same population served as a reference for sTnI plasma levels. A value of 0.04 ng/mL was determined as cut-off value representing the 99th percentile for sensitive troponin I (sTNI, Troponin I Ultra, Siemens Healthcare Diagnostics) using the population of Gutenberg Health Study as previously described. 14 
Statistical Analysis
Receiver operating characteristic (ROC) curves and areas under the curve (AUC) for single biomarkers and combinations of biomarkers were calculated using R package Epicalc. Additionally, measures of the diagnostic accuracy of biomarkers was assessed by applying the above-described specific cut-off values. Cox regression models were used to determine the prognostic value of MPO for the combined end point of cardiovascular death and nonfatal myocardial infarction at 30 days and 6 months. Three models were used to adjust MPO for (1) sex and age, (2) sex, age, BNP, and sTNI, and (3) sTNI, BNP, and parameters of the global registry of acute coronary events (GRACE), risk score including heart rate, creatinine (log-transformed), ST-segment changes in ECG, age, systolic blood pressure, and Killip class. The binary GRACE variable need of defibrillation was not used because of an extreme low number of positives in our cohort.
In a fourth model BNP was adjusted for sex and age. sTNI and BNP were entered as log-transformed variables due to their nonnormal distribution. As AIC (Aikake information criterion) selection demonstrated an unfavorable fit for log-transformation, MPO was entered as untransformed variable. P values were calculated by the Wald z statistic. All statistical analyses were performed with the R software (version 2.10.1).
Results
Study Population
Baseline characteristics of the study population are described in Table 1 Figure 1A and Table 1 ). No relevant difference was found between ST-segment myocardial infarction and non-ST-segment myocardial infarction patients (see online-only Data Supplement Figure I ). Figure 1B furthermore shows MPO plasma levels according to alternative diagnoses made in patients adjudicated with the diagnoses of NCCP. Online-only Data Supplement Figure II shows the comparison of MPO plasma levels for patients diagnosed with noncardiac causes of CP and those with noncoronary, cardiac causes of CP. Compared with patients with CP not related to cardiovascular disease, MPO plasma levels were elevated in patients finally diagnosed with aortic dissection, aortic stenosis, and acute heart failure. No elevation in MPO plasma levels was observed in patients with myocarditis and pulmonary embolism, respectively. Onlineonly Data Supplement Figure III shows the correlation between the investigated biomarkers.
Diagnostic Accuracy of MPO for the Diagnosis of AMI
ROC curves for MPO in comparison to sTNI are presented in Figure 2 , and area under the curves are presented in Table 2 . For all time points (0 hours, 3 hours, and 6 hours after presentation), as well as for patients presenting within 3 hours of symptom onset (not shown), MPO plasma levels yielded a significantly worse accuracy for diagnosing AMI than sTNI. Moreover, the combination of sTNI and MPO did not result in an improvement of the diagnostic accuracy for sTNI ( Table 2 respectively. A detailed presentation of the diagnostic parameters for MPO and sTNI for all patients and patients presenting ≤3 hours after symptom onset is displayed in Table 3 . A B Figure 1 . A, Plasma levels of MPO according to diagnostic groups of acute myocardial infarction (AMI), unstable angina pectoris (UAP), and noncoronary chest pain (NCCP). B, Plasma levels of MPO according to alternative diagnoses not related to coronary artery disease. The box-plot for NCCP summarizes all patients with noncoronary chest pain and contains all the subgroups shown in the graph. The line outside the box indicates cut-off determined in the population-based cohort of 5000 patients. The line within the box indicates median, box 25% and 75% percentile and whiskers 5% and 95% percentiles. The numbers on the top display the observed prevalence.
When restricting analyses to patients presenting with initially negative sTNI, MPO did also not provide substantial additive diagnostic information (online-only Data Supplement Table I ). Because MPO plasma levels are known to be influenced by heparin, we analyzed MPO in a subgroup of 197 patients in relation to administration of heparin. In accordance with previous observations, 17, 18 MPO plasma levels were higher in those patients who had already received heparin than in those who received heparin after blood withdrawal (online-only Data Supplement Figure IV) . However, ROC curves including only patients with normal partial thromboplastin time (n=1076, online-only Data Supplement Figure V) showed comparable diagnostic value of MPO as those including the entire cohort.
Diagnostic Accuracy of MPO for the Diagnosis of ACS
As demonstrated by the ROC curves shown in Figure 2 , MPO also exhibited inferior diagnostic performance compared with sTNI for identifying ACS. Online-only Data Supplement Table II provides parameters of diagnostic performance for MPO and sTNI for the diagnosis of ACS.
Association of MPO With Patient Outcome
The combined end point of cardiovascular death and nonfatal myocardial infarction occurred in 1.2% of patients at 30 days and 3.1% at 6 months in the overall cohort. Cardiovascular death occurred in 1.0% and 1.6% at 30 days and 6 months, respectively. Nonfatal myocardial infarction occurred in 0.3% and 1.6% of patients, respectively. Because of the low rates of isolated events outcome analyses were only performed for the combined end point. MPO plasma levels (entered as continuous variable) obtained at baseline predicted the risk of the combined end point of cardiovascular death and nonfatal myocardial infarction 30 days and 6 months after presentation when adjusted for sex and age. After adjustment for sTNI and BNP, as well as for GRACE score parameters, sTNI and BNP, MPO no longer remained predictive for this end point at 6 months; however, it kept its independent predictive value after adjustment for sTNI and BNP at 30 days (Table 4) . Reclassification analyses also showed no additive information for MPO after adjustment for sTNI (online-only Data Supplement Table III ). Kaplan-Meier estimates for the combined end point of cardiovascular death and nonfatal myocardial ischemia for MPO baseline plasma levels alone and their combination with sTNI and BNP, respectively are shown in Figure 3 .
Diagnostic Accuracy of BNP
ROC curves for BNP in comparison with sTNI and MPO are displayed in Figure 2 . Area under the curves for BNP are displayed in Table 2 . Throughout the studied time-course, BNP did not provide diagnostic information that was additive to sTNI. A detailed description of the diagnostic performance for AMI and ACS of BNP is given in Table 3 and online-only  Data Supplement Table II , respectively.
Association of BNP With Patient Outcome
BNP plasma levels were independently predictive for the combined end point of cardiovascular death and nonfatal myocardial infarction at 6 months in a sex-and age-adjusted analysis. Moreover, BNP remained independently predictive on inclusion of MPO and sTNI into the analysis. However, after additional adjustment for GRACE score parameters, statistical significance was lost. Interestingly, BNP plasma levels were not predictive for the combined end point of cardiovascular death and nonfatal myocardial infarction at 30 days in any of the models (Table 4) . Also, in reclassification analyses BNP did not provide additive information to sTNI (online-only Data Supplement Table III) .
Discussion
This, to our knowledge, represents the largest study investigating the diagnostic and prognostic information of MPO in patients admitted with acute onset of CP. The current trial reconfirms that MPO plasma levels are elevated in patients with AMI. However, the current data also reveal that MPO does not provide clinically relevant information for the diagnosis of AMI when added to sensitive troponin I and hence does not appear to be useful in the management of patients with acute CP in the era of sensitive troponin tests.
In this multicenter study the diagnostic and prognostic properties of MPO were assessed by prospective serial measurements in 1818 consecutive patients presenting with acute CP. For the first time, MPO plasma levels were compared with troponin I as assessed by a recently introduced sensitive assay, the new gold standard for the early diagnosis of AMI. 14, 15 Moreover, and in contrast to previous studies, [11] [12] [13] the current study provides a predefined cut-off value for MPO plasma levels assessed in 5000 population-based subjects. Regardless of the time-point of determination MPO plasma levels yielded a low diagnostic accuracy MPO indicates myeloperoxidase; BNP, B-natriuretic peptide; sTNI, sensitive troponin I; NPV, negative predictive value; PPV, positive predictive value; LR likelihood ratio; pos., positive; and neg., negative.
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with area under the curve ranging from 0.672 to 0.699, depending on the time-point of analysis, which remained clearly inferior to that of sTNI. This low diagnostic accuracy was mainly driven by a low specificity of only 45.5% at presentation compared with a specificity of 90.2% for sTNI. As discussed previously, the low specificity is explained by the fact that leukocyte activation and concomitant release of MPO is not exclusive for ACS. 11 The overall diagnostic accuracy did not improve when analyses were restricted to patients presenting within 3 hours of symptom onset. Interestingly however, and in accordance with previous data the sensitivity of MPO not only tended to improve in these early-presenting patients, but reached that of sTNI. These findings point toward another interesting revelation: the longer the time interval between CP onset and initial blood sampling, the lower the sensitivity and the higher the specificity of MPO to diagnose ACS. This observation is explained by the rapid decline of MPO plasma from presentation to 6 hours after presentation, which implicates that the kinetics of MPO plasma levels differ considerably from that of biomarkers, indicative of myocardial necrosis. In accordance with previous studies 1, 2, 4 this observation supports the notion that the increase of MPO plasma levels after leukocyte activation is an event potentially preceding myocardial necrosis. However, this did not translate into improved accuracy for diagnosing ACS (unstable angina + non-ST-segment myocardial infarction + ST-segment myocardial infarction), further underscoring the fact that MPO does not serve as a valuable additive diagnostic tool to detect patients at risk for myocardial necrosis. Thus, data from a previous study suggested that MPO might be helpful to rule out acute coronary artery disease in patients presenting early after CP onset as its NPV rivaled that of conventional troponin I in this set of patients. Whereas the NPV reported for MPO herein was well within the range of that reported in the previous study, it was clearly worse than that observed for sensitive troponin I. Accordingly, it is fair to conclude that MPO very likely does not provide clinically relevant information when added to sensitive troponin tests.
In our opinion, this improved performance of sTNI compared with conventional troponins is driving the main finding of this study, ie, MPO does not provide clinically relevant additive information for diagnosing acute coronary disease. Thus, it is futile to discuss discrepancies between prior studies investigating the use of MPO as a diagnostic marker in CP patients as For further details about the GRACE Score parameters included into model 4, please refer to the Methods section.
sensitive troponins, which have become state of the art in clinical routine and exhibit diagnostic accuracies clearly exceeding those reported for MPO in any of these previous studies.
11 -13 It was recently reported that heparins increase MPO plasma levels by releasing MPO bound to the vessel wall. 3, 17, 18 Because it is standard-of-care for the treatment of ACS to administer heparin even before hospital admission in the recruiting areas of the study, it is likely that heparin administration confounds the diagnostic and prognostic performance of MPO. Regrettably, heparin administration in relation to blood sampling was only documented in a small subgroup of patients in the current study. Despite the low sample size, these data support the above-described heparin dependency of MPO plasma levels. However, we have recently observed that the MPO release due to leukocyte activation during AMI overrides the effects elicited by heparin. 4 In the present cohort, a large proportion of patients had a partial thromboplastin time below 40 seconds, indicating the absence of heparin administration. In this subset MPO showed comparable diagnostic performance as in the entire cohort supporting our previous observation that AMI overrides heparin effects and therefore extenuating this limitation.
Numerous studies have indicated that MPO independently predicts the outcome of patients with acute CP thus extending the prognostic information provided by biomarkers of myocardial necrosis including troponins. [19] [20] [21] The current study reinforces this tenet insofar as it demonstrates that MPO plasma levels indeed predict adverse events in an age-and sex-adjusted analysis in patients at 30 days and 6 months in patients with ACS and at 30 days even after adjustment for sTNI and BNP. From a pathophysiological perspective, these findings further support the role of specific inflammatory mediators for the longterm fate in cardiovascular disease: activation of leukocytes and in particular neutrophils indicates increased vascular frailty and risk for future vascular events such as plaque rupture.
After adjustment for the established markers sTNI and BNP, the prognostic ability of MPO diminished, however still showing a trend. As the overall number of events during follow up was low it cannot be excluded that in a cohort with higher event rates an additive value of MPO to sTNI and BNP might have been observed.
When focusing on the final diagnoses of patients classified as having noncoronary CP it is important to note that MPO plasma levels are elevated in patients presenting with acute heart failure, which conforms with previous reports suggesting a prognostic role of MPO in this group of patients. [22] [23] [24] However, it has clearly to be pointed out that due to the low number of patients finally diagnosed with heart failure no definite statement can be made about the predictive value of MPO in this subset of patients from our current analyses. Of interest, aortic dissection was also associated with markedly elevated MPO plasma levels, which matches with the concept that endothelial injury of large vessels in accordance to injury in the coronary circulation is firmly linked to leukocyte activation. 25 Importantly, this study also provides results on the diagnostic and prognostic performance of BNP, a biomarker that has not only been proven to be of great clinical usefulness in the evaluation of heart failure patients, 26 but has also been shown to predict the outcome of patients presenting with ACS. 27 According to the data, BNP levels are clearly not useful for the diagnostic evaluation of patients with ACS when added to sensitive troponin. Moreover, BNP levels were not predictive for the shortterm outcome of patients presenting with CP to the emergency department. For the 6-month interval, BNP was predictive even after adjustment for sTNI; however, it lost its predictive value when additionally adjusted for the parameters of the GRACE score. These findings tend to contradict the recently published trial of Meune et al, which found no additional prognostic value for the addition of sensitive troponin (Roche diagnostics) to the GRACE score and a trend for an improved prediction of the 1-year outcome for the addition of BNP. 28 A plausible explanation for the stronger predictive performance of sensitive troponin in our study is likely the fact that our study included CP patients, whereas the study of Meune et al only studied the subgroup of patients with confirmed ACS. As discussed earlier, one further limitation was the low number of events potentially underestimating the prognostic value of the investigated biomarkers. 
CLINICAL PERSPECTIVE
Early diagnosis and risk stratification of patients with acute chest pain is of major importance to improve outcomes in acute coronary syndrome (ACS). By means of biomarkers, many pathophysiologically intriguing approaches have been investigated aiming for early risk stratification of ACS. These novel biomarkers however have to be tested against the improved diagnostic and prognostic performance of high-sensitive troponins, the current gold standard for detection of ACS. The leukocyte-derived heme enzyme myeloperoxidase (MPO) is one such approach, which has yielded promising results in the past. MPO is released upon activation of its host cells, which in the context of ACS is thought to occur during or even before coronary plaque rupture and therefore precedes myocardial ischemia/necrosis. This premise suggest that increased levels of MPO indeed precede the elevation of troponins in the early phase of ACS. Despite these theoretical advantages the current data show a superior diagnostic performance of sensitive troponin I compared with MPO, even in patients presenting early (<2 hours) after chest pain onset. Even though one could speculate that MPO might provide additive diagnostic information in those presenting at even earlier time-points, such early presentations in the absence of definite electrocardiographic or clinical signs of myocardial ischemia remain rare in reality. In contrast, MPO still tends to hold a prognostic potential even in the presence of sensitive troponins, which might be of clinical relevance in the future, with respect to the development of drugs targeting the enzymatic activity of MPO for secondary prevention of cardiovascular events.
